<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04368962</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF2019LSK-038-1</org_study_id>
    <nct_id>NCT04368962</nct_id>
  </id_info>
  <brief_title>DSA Risk Factors in MMF-based Immunosuppressed Post-transplanted Patients</brief_title>
  <acronym>DRFMBIPTP</acronym>
  <official_title>DSA Risk Factors in Chinese Kidney Transplant Patients Using MPA-based Immunosuppression Protocol: A Multi-center Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Kidney transplantation is the best therapy method for patients with uremia. The main factors
      affecting the long-term survival of the graft were chronic antibody-mediated rejection and
      the death of the patients. Newborn donor special antibody (DSA) is a major risk factor for
      chronic antibody-mediated rejection (AMR) and poor transplantation outcomes. Detection of
      mycophenolate mofetil (MMF) trough concentration can help estimate its exposure. Deficient
      exposure of MMF can lead to AMR after transplantation surgery. The aim of this study is to
      estimate the risk factors of one-year DSA after transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">May 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>DSA 12 month</measure>
    <time_frame>2021.5-2023.5</time_frame>
    <description>newborn DSA in recipient serum in the first 12 month after transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>DSA 6 month</measure>
    <time_frame>2020.12-2022.12</time_frame>
    <description>newborn DSA in recipient serum in the first 6 month after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DSA risk factors</measure>
    <time_frame>2020.5-2023.5</time_frame>
    <description>risk factors of newborn DSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPA-AUC</measure>
    <time_frame>2020.5-2023.5</time_frame>
    <description>trough concentration of MMF in recipients' serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AR</measure>
    <time_frame>2020.5-2023.5</time_frame>
    <description>AMR after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>allograft function</measure>
    <time_frame>2021.5-2023.5</time_frame>
    <description>serum creatinine and creatinine clearance in 1 year after transplantation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Antibody-mediated Rejection</condition>
  <arm_group>
    <arm_group_label>MMF group</arm_group_label>
    <description>Post-transplant patients accept immunosuppression protocol based on MMF for at least 12 months.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood sample to dectect MMF trough concentration
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Recipients after kidney transplantation using triple immunosuppression protocol based on
        MMF
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  years 18-65

          -  single organ transplantation

          -  first time to accept kidney transplantation

          -  Triple immunosuppression protocol based on MMF, tacrolimus and glucocorticoid

          -  PRA negative before transplantation

          -  not pregnant for female

        Exclusion Criteria:

          -  Not accept MMF

          -  multi-organ transplantation

          -  pregnancy or lactation period female

          -  mental illness

          -  past tumor, peptic ulcer, severe cardiopulmonary disease, active liver disease history

          -  Cannot regular follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wujun Xue, Prof.</last_name>
    <phone>+86 13991990128</phone>
    <email>xwujun163@mail.xjtu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jin Zheng, Prof.</last_name>
    <phone>+86 18133916118</phone>
    <email>jzheng@mail.xjtu.edu.cn</email>
  </overall_contact_backup>
  <reference>
    <citation>Huang J, Millis JM, Mao Y, Millis MA, Sang X, Zhong S. Voluntary organ donation system adapted to Chinese cultural values and social reality. Liver Transpl. 2015 Apr;21(4):419-22. doi: 10.1002/lt.24069. Epub 2015 Feb 13.</citation>
    <PMID>25545626</PMID>
  </reference>
  <reference>
    <citation>Miettinen J, Per√§saari J, Lauronen J, Qvist E, Valta H, Pakarinen M, Merenmies J, Jalanko H. Donor-specific HLA antibodies and graft function in children after renal transplantation. Pediatr Nephrol. 2012 Jun;27(6):1011-9. doi: 10.1007/s00467-011-2007-6. Epub 2011 Oct 13.</citation>
    <PMID>21993970</PMID>
  </reference>
  <reference>
    <citation>Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004 Mar;4(3):378-83.</citation>
    <PMID>14961990</PMID>
  </reference>
  <reference>
    <citation>Ginevri F, Nocera A, Comoli P, Innocente A, Cioni M, Parodi A, Fontana I, Magnasco A, Nocco A, Tagliamacco A, Sementa A, Ceriolo P, Ghio L, Zecca M, Cardillo M, Garibotto G, Ghiggeri GM, Poli F. Posttransplant de novo donor-specific hla antibodies identify pediatric kidney recipients at risk for late antibody-mediated rejection. Am J Transplant. 2012 Dec;12(12):3355-62. doi: 10.1111/j.1600-6143.2012.04251.x. Epub 2012 Sep 7.</citation>
    <PMID>22959074</PMID>
  </reference>
  <results_reference>
    <citation>Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettenger RE, Agodoa LY, Held PJ, Port FK. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999 Dec 2;341(23):1725-30.</citation>
    <PMID>10580071</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>April 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

